PHASE III RANDOMIZED STUDY: ORAL PILOCARPINE VERSUS SUBMANDIBULAR SALIVARY GLAND TRANSFER PROTOCOL FOR THE MANAGEMENT OF RADIATION-INDUCED XEROSTOMIA

被引:49
作者
Jha, Naresh [1 ]
Seikaly, Hadi [2 ]
Harris, Jeffrey [2 ]
Williams, David [3 ]
Sultanem, Khalil [4 ]
Hier, Michael [5 ]
Ghosh, Sunita [6 ]
Black, Martin [5 ]
Butler, James [7 ,8 ]
Sutherland, Donna [9 ]
Kerr, Paul [9 ,10 ]
Barnaby, Pam [1 ]
机构
[1] Univ Alberta, Cross Canc Inst, Dept Radiat Oncol, Edmonton, AB, Canada
[2] Univ Alberta, Dept Surg, Div Otolaryngol, Edmonton, AB, Canada
[3] Univ Alberta, Dept Surg, Div Head & Neck Surg, Edmonton, AB, Canada
[4] McGill Univ, Jewish Gen Hosp, Div Radiat Oncol, Dept Oncol, Montreal, PQ H3T 1E2, Canada
[5] McGill Univ, Jewish Gen Hosp, Div Otolaryngol, Dept Surg, Montreal, PQ H3T 1E2, Canada
[6] Univ Alberta, Cross Canc Inst, Dept Expt Oncol, Edmonton, AB, Canada
[7] Univ Manitoba, Dept Radiat Oncol, Canc Care Manitoba, Winnipeg, MB, Canada
[8] Univ Manitoba, Dept Radiol, Canc Care Manitoba, Winnipeg, MB, Canada
[9] Univ Manitoba, Dept Surg Oncol, Canc Care Manitoba, Winnipeg, MB, Canada
[10] Univ Manitoba, Dept Otolaryngol, Winnipeg, MB, Canada
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2009年 / 31卷 / 02期
关键词
xerostomia; salivary gland transfer procedure; radiation; pilocarpine; cancer; INTENSITY-MODULATED RADIOTHERAPY; QUALITY-OF-LIFE; DOSE RADIOIODINE TREATMENT; NECK-CANCER PATIENTS; DOUBLE-BLIND; NASOPHARYNGEAL CARCINOMA; CLINICAL-TRIALS; HEAD; AMIFOSTINE; EFFICACY;
D O I
10.1002/hed.20961
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Xerostomia is a serious morbidity of radiation treatment in head and neck cancer. Methods. We conducted a prospective phase III multicenter randomized study comparing submandibular salivary gland transfer (SGT) procedure with pilocarpine during and for 3 months after XRT. Salivary flow (baseline, stimulated) and University of Washington Quality of Life Questionnaire (U of W QOL) scores were measured. Results. An interim intent to treat analysis (120 patients) at 6 months shows superior results in SGT arm: median baseline salivary flow for SGT (0.04 mL/minute) versus pilocarpine (0.01 mL/minute), p = .001, median stimulated salivary flow (0.18 mL/minute) for SGT versus (0.05 mL/minute) for pilocarpine, p = .003. Scores (U of W COL) for amount (p = .017) and consistency of saliva (p = .005) in favor of SGT leading to premature closure of study. Conclusions. Submandibular SGT procedure is superior to pilocarpine in management of radiation-induced xerostomia. (C) 2008 Wiley Periodicals, Inc. Head Neck 31: 234-243, 2009
引用
收藏
页码:234 / 243
页数:10
相关论文
共 42 条
[1]  
Blom M, 2000, ORAL DIS, V6, P15
[2]   Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study [J].
Bohuslavizki, KH ;
Klutmann, S ;
Brenner, W ;
Mester, J ;
Henze, E ;
Clausen, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3542-3549
[3]  
Bohuslavizki KH, 1999, STRAHLENTHER ONKOL, V175, P6
[4]  
Bohuslavizki KH, 1998, J NUCL MED, V39, P1237
[5]   Phase III randomized trial of amifostine as a radioprotector in head and neck cancer [J].
Brizel, DM ;
Wasserman, TH ;
Henke, M ;
Strnad, V ;
Rudat, V ;
Monnier, A ;
Eschwege, F ;
Zhang, J ;
Russell, L ;
Oster, W ;
Sauer, R .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3339-3345
[6]   Intensity-modulated radiotherapy: Is xerostomia still prevalent? [J].
Chambers M.S. ;
Garden A.S. ;
Rosenthal D. ;
Ahamad A. ;
Schwartz D.L. ;
Blanco A.I. ;
Chao K.S.C. ;
Morrison W.H. ;
Ang K.K. ;
Weber R.S. .
Current Oncology Reports, 2005, 7 (2) :131-136
[7]  
CHENCHARICK JD, 1983, CANCER-AM CANCER SOC, V51, P811, DOI 10.1002/1097-0142(19830301)51:5<811::AID-CNCR2820510511>3.0.CO
[8]  
2-M
[9]   CIRCADIAN-RHYTHMS IN FLOW-RATE AND COMPOSITION OF UNSTIMULATED AND STIMULATED HUMAN SUBMANDIBULAR SALIVA [J].
DAWES, C .
JOURNAL OF PHYSIOLOGY-LONDON, 1975, 244 (02) :535-548
[10]  
DAWES C, 1996, BRIT DENT J